16
APR
2013

NW Bio’s Phase III Trial With DCVax®-L For Brain Cancer “Adopted” As A National Priority Trial In UK

Posted By :
Comments : Off
Trial Sites Will Receive Support from UK Health System BETHESDA, Md., April 16, 2013 — Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the Company’s Phase III clinical trial for Glioblastoma multiforme (GBM) brain cancer has been “adopted” as a national priority trial in the UK, under the...
Read More
08
APR
2013

NW Bio 2012 Annual Report Shows Strong Progress And Enhancement Of Leadership Position

Posted By :
Comments : Off
NW Bio 2012 annual report shows strong progress and enhancement of leadership position
Read More
19
MAR
2013

NW Bio To Review Its Leadership Position In Immune Therapy At The 25th Annual Roth Conference

Posted By :
Comments : Off
CEO Will Discuss Key Strengths and Progress, Announce New Developments BETHESDA, Md., March 19, 2013 — Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that Linda F. Powers, the Company’s Chairman and Chief Executive Officer, will be presenting at the 25th Annual ROTH Conference at 8:30 a.m. PDT on Wednesday, March...
Read More
18
MAR
2013

NW Bio Receives U.S. Patent On Broad Processes For Producing More Potent Dendritic Cells

Posted By :
Comments : Off
Next Generation Technology Already In DCVax®-Direct; Will Be Applicable To All DCVax® Products BETHESDA, Md., March 18, 2013 — Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has been issued a key U.S. patent (#8389278) covering novel processes for manufacturing human dendritic cells.  The cells produced...
Read More
12
MAR
2013

NW Bio Establishes Cross-Border Manufacturing And Distribution For DCVax® In Europe

Posted By :
Comments : Off
Approvals Expanding the Scope of German Manufacturing Are Key Steps BETHESDA, Md., March 12, 2013 — Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the Company has taken a key step in building Europe-wide arrangements for manufacturing and distribution of DCVax.  This represents a major area of competitive...
Read More